How should a gout tophus be treated in an adult patient with chronic gout who has not achieved target serum urate despite maximally tolerated xanthine‑oxidase inhibitor therapy?

Treatment of Gout Tophus in Patients Failing Maximal XOI Therapy

For patients with gout tophi who have not achieved target serum urate despite maximally tolerated xanthine oxidase inhibitor therapy, add a uricosuric agent (such as probenecid) to create combination urate-lowering therapy, or escalate to pegloticase if combination therapy fails or tophi are severely debilitating.

Algorithmic Treatment Approach

Step 1: Add Combination Therapy with Uricosuric

• Add probenecid (starting 500 mg once to twice daily with dose titration) to your existing maximized XOI therapy 1
• Combination therapy with a uricosuric plus XOI provides substantially greater serum urate lowering than either monotherapy alone and translates to improved tophus resolution 2
• This approach is specifically recommended in guidelines for patients who do not meet treatment targets with XOI monotherapy 2
• Target serum urate: <6 mg/dL (360 μmol/L), though some guidelines recommend <5 mg/dL (300 μmol/L) for tophaceous disease 3, 4

Step 2: Consider Pegloticase for Refractory Cases

If combination therapy fails to achieve target serum urate or tophi continue to progress:

• Pegloticase is the definitive option for refractory tophaceous gout, though it is strongly recommended against as first-line therapy 1
• Pegloticase degrades uric acid to allantoin (more soluble) and is FDA-approved for patients with refractory chronic gout 3
• Critical caveat: Consider co-administration with methotrexate to reduce immunogenicity from anti-pegloticase antibodies and improve efficacy 5

Step 3: Maintain Anti-inflammatory Prophylaxis

• Strongly recommended: Continue colchicine, NSAIDs, or prednisone/prednisolone for 3-6 months minimum during any ULT intensification 1
• Continue prophylaxis longer if flares persist, as aggressive urate lowering can initially mobilize crystals and trigger flares

Step 4: Surgical Intervention When Indicated

For tophi causing:

• Chronic non-healing ulcers (tophaceous wounds)
• Significant tissue loss or functional impairment
• Joint deformity requiring reconstruction

Surgical options include debridement (sharp, ultrasonic, micro-techniques), skin flap grafting, and tendon/ligament reconstruction 4, 6. Surgery should be coordinated with achieving serum urate <300 μmol/L to prevent recurrence 4.

Key Clinical Considerations

Monitoring Requirements:

• Check serum urate levels regularly during dose titration
• For combination therapy, assess response within 3-6 months
• Local uric acid monitoring can assess debridement efficacy if surgical intervention needed 4

Common Pitfalls to Avoid:

1. Don't abandon XOI therapy when adding uricosuric—the combination is synergistic 2
2. Don't skip anti-inflammatory prophylaxis—aggressive urate lowering without prophylaxis dramatically increases flare risk 1
3. Don't delay pegloticase excessively in severely debilitating tophaceous disease—years of inadequate control lead to irreversible joint damage 7
4. Ensure adequate renal function before using probenecid (contraindicated in moderate-to-severe CKD) 1

Evidence Quality Discussion

The 2020 ACR guideline 1 provides the strongest framework, with moderate-quality evidence supporting the treat-to-target approach and combination therapy strategy. The combination therapy recommendation is reinforced by a comprehensive 2019 review 2 showing consistent benefit across multiple studies. While pegloticase evidence is also moderate quality, the ACR strongly recommends against first-line use due to cost and safety concerns, reserving it for truly refractory cases 1.

The emerging data on methotrexate co-administration with uricases 5 and advanced wound management strategies 4 represent important adjunctive considerations, though these are based on lower-quality evidence (case reports and expert consensus).

The critical principle: Achieving and maintaining serum urate below saturation point dissolves crystal deposits and enables tophus resolution, but this requires aggressive, sustained therapy that most primary care settings underutilize 8.